Please login to the form below

Not currently logged in

FDA approves first drug for lipodystrophy

The US Food and Drug Administration has approved Egrifta as the first treatment for HIV patients with lipodystrophy

The US Food and Drug Administration (FDA) has approved Egrifta (tesamorelin) as the first treatment for HIV patients with lipodystrophy, a condition in which excess fat develops around the liver, stomach, and other abdominal organs, as well as in other places in the body.

Egrifta was developed by the Canadian company Theratechnologies and will be marketed in the US by EMD Serono, an affiliate of Germany's Merck KGaA. The product is a growth hormone releasing factor drug that is administered as a once-daily injection.

Lipodystrophy, which is associated with many antiretroviral drugs used to treat HIV, can contribute to other health problems as well as negatively affect quality of life, the FDA noted. The clinical studies conducted by Theratechnologies did not evaluate whether Egrifta decreases the risk of cardiovascular disease or improves compliance with antiretroviral drugs.

The placebo-controlled studies submitted to the FDA by the company involved a total of 816 HIV-infected adults with lipodystrophy and excess abdominal fat. The studies showed that patients treated with Egrifta experienced greater reductions in abdominal fat as measured by CT scan than were experienced by patients given a placebo injection.

EMD Serono acquired the US rights to the drug in late 2008, while the product was in phase III, under a deal that could be worth up to $215m to Theratechnologies. Under the agreement, Theratechnologies received an upfront payment of $30m, including a licence fee of $22m and an equity investment of $8m by Merck KGaA. The Canadian company is also entitled to development, regulatory and sales milestones, as well as increasing royalties on annual net sales of tesamorelin in the US.

EMD Serono also has an option to participate in future indications in the US, with Theratechnologies maintaining the right, subject to EMD Serono's agreement, to co-promote the additional uses. Egrifta has therapeutic potential in a variety of anabolic and lipolytic indications, according to the companies.

12th November 2010


Featured jobs

Subscribe to our email news alerts


Add my company
VCCP Health

We’re the challenger agency for challenger brands. Brands with a point to prove. Rx, OTC and wellness brands run by...

Latest intelligence

Navigating the antibiotic resistance crisis
Blue Latitude Health speaks to Tara DeBoer, PhD, Postdoctoral Researcher and CEO of BioAmp Diagnostics to explore the antimicrobial resistance crisis, and learn how a simple tool could support physicians...
Combined immunotherapies – potential and pitfalls
‘Combining therapeutic compounds is the first logical step towards better results, namely higher rates of patients responding to treatment, with deeper and more sustained responses’...
Report: Achieving launch excellence in the challenging healthcare markets of today
Our in-depth report is based on original data and expert interviews, which coupled with our own experience, ensures we give you the best recommendations for achieving launch success in challenging...